NCT07279090

Brief Summary

This study aims to explore the dynamic changes in different cell types and their molecular regulatory mechanisms during the healing process of peri-implant soft tissues, using single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics (ST). The research will focus specifically on the healing of soft tissues around dental implants in human subjects with the use of a healing abutment. Participants in the healing abutment group will have a micro healing abutment placed immediately after implant placement. Tissue samples will be collected at various time points (Day 4, Day 14, and Day 70) to construct a detailed single-cell map of the healing process. Spatial transcriptomics will be integrated to preserve tissue architecture, enabling the identification of the spatial distribution of different cell types and their interactions within the peri-implant microenvironment. This combined approach will allow for a comprehensive characterization of cellular interactions, spatial gene expression patterns, and regulatory networks specific to healing abutments. The goal is to identify key regulatory factors that could improve peri-implant soft tissue healing and help prevent peri-implantitis.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
5

participants targeted

Target at below P25 for not_applicable

Timeline
8mo left

Started Dec 2025

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress37%
Dec 2025Dec 2026

First Submitted

Initial submission to the registry

September 16, 2025

Completed
3 months until next milestone

First Posted

Study publicly available on registry

December 12, 2025

Completed
8 days until next milestone

Study Start

First participant enrolled

December 20, 2025

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2026

Expected
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2026

Last Updated

December 16, 2025

Status Verified

December 1, 2025

Enrollment Period

12 months

First QC Date

September 16, 2025

Last Update Submit

December 13, 2025

Conditions

Keywords

Peri-implant soft tissue healingscRNA-seq

Outcome Measures

Primary Outcomes (5)

  • Primary Outcome 1: Differentially Expressed Genes (DEGs) in Peri-implant Soft Tissues

    Number of genes significantly differentially expressed between experimental groups, determined by single-cell RNA sequencing (scRNA-seq) analysis (FDR \< 0.05). Unit of Measure: Number of genes.

    Day 4, Week 2, Week 4 and Week 8-10 post-implantation.

  • Cell Type Composition in Peri-implant Soft Tissues

    Proportion (%) of each annotated cell type identified by scRNA-seq based on canonical marker expression. Unit of Measure: Percentage of total cells (%)

    Day 4, Week 2, Week 4, and Week 8-10 post-implantation.

  • Enriched Biological Pathways

    Number of significantly enriched Gene Ontology (GO) terms and KEGG pathways identified from DEGs (FDR \< 0.05). Unit of Measure: Number of enriched terms/pathways

    Day 4, Week 2, Week 4, and Week 8-10 post-implantation

  • Ligand-Receptor Interaction Strength

    Mean interaction score of ligand-receptor pairs identified among annotated cell types using CellPhoneDB (or equivalent computational tool). Unit of Measure: Interaction score (arbitrary units)

    Day 4, Week 2, Week 4, and Week 8-10 post-implantation

  • Spatial Gene Expression Patterns

    Localization and expression intensity of selected DEGs across tissue regions determined by the 10x Genomics Visium platform.

    Day 4, Week 2, Week 4 and Week 8-10 post-implantation.

Secondary Outcomes (4)

  • Histological Tissue Morphology

    Day 4, Week 2, Week 4 and Week 8-10 post-implantation.

  • Immune and Stromal Cell Quantification

    Day 4, Week 2, Week 4 and Week 8-10 post-implantation.

  • Junctional Epithelium Length

    Day 4, Week 2, Week 4, and Week 8-10 post-implantation.

  • Basement Membrane Protein Expression

    Day 4, Week 2, Week 4, and Week 8-10 post-implantation.

Study Arms (1)

Healing Abutment Gingival Healing Post-Implantation

EXPERIMENTAL
Procedure: Healing Abutment Gingival Healing Post-Implantation

Interventions

The healing process of peri-implant soft tissues will be studied using a micro healing abutment (2 mm), which will be placed at least three months after implant Stage I surgery. Gingival tissue samples will then be collected at Day 4, Week 2, Week 4, and Week 8-10. At each time point, a circular incision around the micro abutment will be made using a circular punch, and the gingival tissue together with the abutment will be retrieved under local anesthesia. After sampling, the micro abutment will be replaced with a formal healing abutment to maintain healing. Samples will undergo single-cell RNA sequencing (scRNA-seq) to characterize cell types, gene expression changes, and regulatory pathways involved in soft tissue repair. Additional tissues will be used for spatial transcriptomics (ST) and histological staining.

Healing Abutment Gingival Healing Post-Implantation

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age: 18-65 years
  • Healthy individuals without chronic medical conditions or severe systemic diseases
  • Able to comply with study requirements (e.g., follow-up visits)
  • No history of periodontal disease or active infection
  • Already completed four or more implant placements in the posterior tooth region
  • Adequate gingival thickness to allow for sampling and proper healing

You may not qualify if:

  • Individuals with systemic conditions that affect wound healing (e.g., diabetes, immunosuppressive therapy)
  • Smoking or alcohol abuse
  • Pregnant or breastfeeding women
  • History of severe allergic reactions to implant materials
  • Participation in another clinical study at the same time

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

School and Hospital of Stomatology, Fujian Medical University

Fuzhou, Fujian, 350004, China

Location

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
BASIC SCIENCE
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor of Prosthodontics

Study Record Dates

First Submitted

September 16, 2025

First Posted

December 12, 2025

Study Start

December 20, 2025

Primary Completion (Estimated)

December 1, 2026

Study Completion (Estimated)

December 31, 2026

Last Updated

December 16, 2025

Record last verified: 2025-12

Locations